The agreement will provide AUM with exclusive worldwide rights to develop, manufacture and commercialise these inhibitors with Inflection receiving an upfront payment, milestone payments and royalties on future sales.
Known as the IBL-300 series of molecules, the agreement will see AUM develop the lead candidate, IBL-302 (hereafter AUM302), which is currently in the pre-clinical stage of development.
AUM302 is a first-in-class kinase inhibitor designed to inhibit three critical cancer targets (pan-PIM kinase, pan-PI3K and mTOR inhibition) via a single molecule.
Inhibiting these three targets has synergistic anticancer effects and has been shown to be more effective than inhibiting the targets alone.
AUM302 has been evaluated in over 700 cancer cell lines and has shown potential for clinical development in breast cancer, lung cancer, leukaemia and neuroblastoma. AUM plans to commence Investigational New Drug enabling studies for AUM302 by 2020.
Inflection was advised by Oncology Partners LLC, New York.
Inflection Biosciences Ltd, based in Dublin, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of innovative cancer treatments was licensed from the Spanish National Cancer Research Centre.
The pipeline comprises the first-in-class dual mechanism kinase inhibitors AUM-300 series (PIM/PI3K/mTOR inhibitors) partnered with AUM Biosciences, and internal programmes IBL-202 (PIM/PI3K inhibitor) and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Inflection Biosciences was named 'Start-up company of the Year' at the 2014 Irish Pharma Awards.
AUM Biosciences is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies.
Dedicated to unlocking the value in innovation, we harness the power of precision medicine, and digital health to support patients, physicians and our partners.
AUM focuses on early-stage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.
Led by a highly-experienced management team with over 100 years of oncology drug development experience combined, AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs.
Headquartered in Singapore, AUM is strategically positioned to work with, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost and Sullivan's 2019 Asia-Pacific Biotech Entrepreneurial company of the Year.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval